| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Related Medications Threads on Diabetes Health Forums
The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.
1 comment - Mar 12, 2010 -
The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.
1 comment - Mar 5, 2010 -
If you regularly take metformin, one of the oldest and most respected tools in doctors' anti-diabetes kits, chances are that you don't detect the unpleasant odor that turns some type 2s against the drug. Some think it has fishy smell, while others say that it reminds them of the inside of an inner tube.
6 comments - Mar 4, 2010 -
A California study that tracked 77 obese adolescents for almost two years indicates that metformin XR, an extended-release version of the popular anti-diabetic drug, may help lower body mass index in overweight teens who do not have diabetes.
1 comment - Feb 10, 2010 -
A South African university pharmacologist has found that simultaneous consumption of metformin and grapefruit juice raises lactic acid to dangerous levels in rats (and conceivably in people) with type 2 diabetes. Too much acid in the blood can cause low pH levels that interfere with the body's metabolic functions. Conceivably, says Dr. Peter Owira, a pharmacologist at the University of KawZulu-Natal, such low levels could be fatal.
4 comments - Oct 26, 2009 -
Metformin has always been the old reliable for treating new onset type 2 diabetes, but it's beginning to look like it's got a new calling as a cancer treatment. Diabetes Health recently reported on the fact that metformin reduces a type 2 person's risk of pancreatic cancer by up to 62 percent. It's also been observed that people with type 2 who take metformin have a much lower cancer incidence than those who don't. Now it appears that metformin can help with breast cancer treatment as well. A study of mice with breast cancer generated from human breast cancer cells has found that they remained tumor-free for nearly three months on metformin combined with doxorubicin, a standard cancer chemotherapy. In mice given only the doxorubicin, the tumors recurred.
1 comment - Sep 25, 2009 -
Adults newly diagnosed with type 2 diabetes generally don't take to the idea of using insulin right off the bat. They're worried about gaining weight and fear low blood sugars. They're also concerned about whether they can manage the regimen and fear that taking insulin will lower their quality of life. Those concerns, however, might be assuaged by a study recently conducted by Ildiko Lingvay and his colleagues at the University of Texas Southwestern.
5 comments - Sep 12, 2009 -
Metformin is one of the oldest and most tried-and-true diabetes treatments around, but apparently it has a new talent. According to research from the M.D. Anderson Cancer Center at the University of Texas, good ol' metformin reduces a type 2 person's risk of pancreatic cancer by 62 percent.
2 comments - Aug 5, 2009 -
CRx-401, an insulin sensitizer intended to assist metformin in type 2 diabetes therapy, has successfully completed a Phase 2 clinical trial in which patients taking it saw their fasting plasma glucose drop by 12 mg/dl after 90 days.
1 comment - Jun 3, 2009 -
A study of Merck's Januvia (sitagliptin), a drug for patients with type 2 diabetes, has found that its use can lead in some patients to a low-grade form of pancreatitis and an increased risk of pancreatic cancer in the long term. However, the study, conducted at the Larry L. Hillblom Islet Research Center at UCLA, also found that the risks associated with Januvia as a monotherapy are removed when the drug is used in conjunction with metformin (trade name Glucophage). Metformin, a low-cost drug that controls glucose production by the liver, is one of the oldest and most benign standbys in the anti-diabetes arsenal.
0 comments - May 27, 2009 -